AU2001240982A1 - Method for diagnosing efficacy of xenotypic antibody therapy - Google Patents

Method for diagnosing efficacy of xenotypic antibody therapy

Info

Publication number
AU2001240982A1
AU2001240982A1 AU2001240982A AU2001240982A AU2001240982A1 AU 2001240982 A1 AU2001240982 A1 AU 2001240982A1 AU 2001240982 A AU2001240982 A AU 2001240982A AU 2001240982 A AU2001240982 A AU 2001240982A AU 2001240982 A1 AU2001240982 A1 AU 2001240982A1
Authority
AU
Australia
Prior art keywords
antibody therapy
xenotypic antibody
diagnosing
efficacy
diagnosing efficacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001240982A
Other versions
AU2001240982B2 (en
Inventor
Antoine Noujaim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altarex Medical Corp
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Priority claimed from PCT/IB2001/000423 external-priority patent/WO2001059452A2/en
Publication of AU2001240982A1 publication Critical patent/AU2001240982A1/en
Assigned to ALTAREX MEDICAL CORP. reassignment ALTAREX MEDICAL CORP. Request for Assignment Assignors: ALTAREX CORP.
Application granted granted Critical
Publication of AU2001240982B2 publication Critical patent/AU2001240982B2/en
Priority to AU2006203074A priority Critical patent/AU2006203074A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001240982A 2000-02-08 2001-02-08 Method for diagnosing efficacy of xenotypic antibody therapy Ceased AU2001240982B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006203074A AU2006203074A1 (en) 2000-02-08 2006-07-18 Method for diagnosing efficacy of xenotypic antibody therapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18100800P 2000-02-08 2000-02-08
US60181008 2000-02-08
US20186800P 2000-05-04 2000-05-04
US60201868 2000-05-04
PCT/IB2001/000423 WO2001059452A2 (en) 2000-02-08 2001-02-08 Method for diagnosing efficacy of xenotypic antibody therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006203074A Division AU2006203074A1 (en) 2000-02-08 2006-07-18 Method for diagnosing efficacy of xenotypic antibody therapy

Publications (2)

Publication Number Publication Date
AU2001240982A1 true AU2001240982A1 (en) 2001-11-01
AU2001240982B2 AU2001240982B2 (en) 2006-05-04

Family

ID=26876809

Family Applications (2)

Application Number Title Priority Date Filing Date
AU4098201A Pending AU4098201A (en) 2000-02-08 2001-02-08 Method for diagnosing efficacy of xenotypic antibody therapy
AU2001240982A Ceased AU2001240982B2 (en) 2000-02-08 2001-02-08 Method for diagnosing efficacy of xenotypic antibody therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU4098201A Pending AU4098201A (en) 2000-02-08 2001-02-08 Method for diagnosing efficacy of xenotypic antibody therapy

Country Status (11)

Country Link
US (1) US20020022235A1 (en)
EP (1) EP1254374B1 (en)
JP (1) JP2003522774A (en)
AT (1) ATE360212T1 (en)
AU (2) AU4098201A (en)
CA (1) CA2399067A1 (en)
DE (1) DE60127935T2 (en)
DK (1) DK1254374T3 (en)
ES (1) ES2284624T3 (en)
PT (1) PT1254374E (en)
WO (1) WO2001059452A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
ES2304264A1 (en) * 2001-10-26 2008-10-01 Altarex Medical Corp. Combination therapy for treating disease
US20050260208A1 (en) * 2002-04-11 2005-11-24 Altarex Medical Corp. Binding agents and their use in targeting tumor cells
US20050271649A1 (en) * 2002-10-17 2005-12-08 Schultes Birgit C Therapeutic adjuvant

Similar Documents

Publication Publication Date Title
AU2001294175A1 (en) Method of purifying antibody
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001241075A1 (en) Method of anticipating interaction between proteins
AU2001297856A1 (en) Method for determining homeostasis of the skin
AU2001286983A1 (en) Method of treatment
AU2001257903A1 (en) Method for treatment of neurodegenerative diseases
AU2002221906A1 (en) Method for diagnosing allergic diseases
AU5441000A (en) Human monoclonal antibody
AU2002214286A1 (en) Method of profiling protein
AU2002247141A1 (en) Method for evaluating therapeutic efficacy
AU2001240982A1 (en) Method for diagnosing efficacy of xenotypic antibody therapy
AU2002256053A1 (en) Novel bgp compounds for therapy and diagnosis and methods for using same
AU2001294258A1 (en) Method of purifying plavastatin
AU2001267922A1 (en) Method of assaying the function of fc fragment of antibody
AU2001262177A1 (en) Method of treatment
AU2001274552A1 (en) Method of fundamentally treating common cold
AU2001245552A1 (en) Transcutaneous immunization for large particulate antigens
AU2002354363A1 (en) Method of activating protein
AU2002232563A1 (en) Compounds for therapy and diagnosis and methods for using same
AU2002367463A1 (en) NOVEL p53BP2 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME
AU2003286850A1 (en) ANTIGENIC gp 100 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME
AU2001286268A1 (en) Method of forming complex
AU2001272529A1 (en) Monoclonal antibody against human cathepsin w
AU2001258611A1 (en) Method of diagnosis
AU2002224900A1 (en) Method for the preparation of dichlorodiarylmethanes